Baidu
map

Ann Rheum Dis:银屑病,尤忌吸烟(DANBIO注册研究)

2015-11-30 MedSci MedSci原创

目的:银屑病在常规护理中使用第一肿瘤坏死因子抑制剂(TNFi),本次旨在研究在这种治疗方式下吸烟对银屑病的活动性、依从性和治疗反应性的影响。方法:观察性队列研究,数据由丹麦全国性DANBIO登记处提供,通过吸烟状态分组(目前吸烟、曾吸烟、从不吸烟),采用K-M曲线、logistics和cox回归曲线分析治疗的依从性、反应性(ACR20/50/70、SULAR良好反应性)。另外根据性别和TNFi亚型

目的:银屑病在常规护理中使用第一肿瘤坏死因子抑制剂(TNFi),本次旨在研究在这种治疗方式下吸烟对银屑病的活动性、依从性和治疗反应性的影响。

方法:观察性队列研究,数据由丹麦全国性DANBIO登记处提供,通过吸烟状态分组(目前吸烟、曾吸烟、从不吸烟),采用K-M曲线、logistics和cox回归曲线分析治疗的依从性、反应性(ACR20/50/70、SULAR良好反应性)。另外根据性别和TNFi亚型进行多层分析。

结局:研究纳入1388例银屑病病例,1148例(83%)已知吸烟状况(目前吸烟33%,从不吸烟41%,曾吸烟26%)。中位随访时间为1.22年(IQR 0.44-2.96)。在基线,目前吸烟组较从不吸烟组的BMI指数更低(27 kg/m2 (23–30)/28 kg/m2 (24–31)) (中位 (IQR)),病程更短(3年(1-8)/5年(2-10)),肿胀指数更低(2(0–5)/3(1–6)),视觉模拟评分(VAS) (72 mm (54–87)/68 mm (50–80))和视觉模拟疲劳评分(72 mm (51–86)/63 mm (40–77)),以及健康问卷评分均更高(HAQ)(1.1 (0.7 to 1.5)/1.0 (0.5-1.5))(所有的P<0.05)。目前吸烟者较从不吸烟的治疗依从性更差(1.56 年(0.97- 2.15)/2.43 年 (1.88-2.97), (中位 (95% CI)), log rank p=0.02),以及更差的6个月的EULAR良好反应率(23%/34%),ACR20(24%/33%),ACT50反应率(17%/24%)(所有P<0.05),男性患者最为明显。在目前吸烟的患者中,英夫利昔单抗(抗类风湿药)(HR 1.62,95%CI 1.06-2.48)和依那西普(HR 1.74,95%CI 1.14-2.66)的治疗依从性更差,而阿达木单抗则不是(HR 0.80, 0.52 - 1.23)。

结论:吸烟的银屑病病人较不吸烟的在基线时患者自我报告的结局更差,治疗依从性更短,TNFi的反应性更低。这些影响在男性病人和使用英夫利昔单抗和依那西普治疗的病人中表现得更明显。


原始出处:
Hojgaard, P., et al. (2015). "Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry." Ann Rheum Dis 74(12): 2130-2136.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2016-06-12 cmj8wellington
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2016-01-03 卡莲

    有意思

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2016-05-23 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2015-12-02 zhyy93
  6. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2015-12-01 三三五五

    有意思!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2012045, encodeId=9910201204584, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 12 11:47:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764755, encodeId=19881e6475502, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Sat Oct 29 17:47:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51371, encodeId=6176513e189, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4e21675717, createdName=卡莲, createdTime=Sun Jan 03 08:07:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917223, encodeId=5229191e22357, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 23 16:47:00 CST 2016, time=2016-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556725, encodeId=61da1556e2539, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Dec 02 09:47:00 CST 2015, time=2015-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44258, encodeId=1b8144258be, content=有意思!, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 01 13:21:00 CST 2015, time=2015-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44232, encodeId=c72544232e9, content=副银屑病该如何治疗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=974f1667182, createdName=杨晨舟, createdTime=Tue Dec 01 00:47:00 CST 2015, time=2015-12-01, status=1, ipAttribution=)]
    2015-12-01 杨晨舟

    副银屑病该如何治疗?

    0

相关资讯

世界银屑病日:关注银屑病遗传易感性

银屑病是一种具有遗传倾向的慢性、复发性、炎症性疾病,可累及多个系统。从患者角度而言,银屑病严重影响形象及生活质量,被比作无法根治的慢性癌症。目前全球银屑病患者已达到了1.25亿之多,而我国银屑病患者数量约800万。 2004年7月,来自世界各地的银屑病患者和非银屑病患者代表组成了银屑病指导委员会。同时,由国际银屑病协会(IFPA)提出,会议一致通过将今后每年10月29日定为“世界银屑病日”。目前

强生银屑病治疗药IL-23拮抗剂临床IIb期获得成功

近日,强生公司(J&J)开发的IL-23拮抗剂Guselkumab临床IIb期获得喜人成果,86%的受试者在接受100mg药物注射治疗后,实现皮损症状消除。在该阶段试验中,Guselkumab效果完胜安慰剂组,并优于艾伯维公司银屑病治疗旗舰产品阿达木单抗(Humira)。 临床IIb期试验结果表明:进行16周治疗后,100mg剂量组的皮损症状消除效果最佳,其中86%患者在使用该剂量药物后

JAMA:看银屑病与葡萄膜炎如何基情四射!

牛皮癣,即银屑病,是一种炎症性皮肤病,更严重的情况下也可侵犯关节。葡萄膜炎是眼中间层的一种炎症性疾病,它与银屑病的免疫反应相似。尽管二者之间可能存在某种联系,但是银屑病或银屑病性关节炎患者发生葡萄膜炎的风险也有限。 本研究旨在更好地了解二者之间的关系,研究人员发现银屑病、银屑病性关节炎与葡萄膜炎之间具有双向的促进作用。使用全国性的数据库可满足研究人员进行如此大规模的队列研究以分析二者之间的关

JAMA Dermatol:银屑病患者抑郁风险增加

银屑病是一种系统性、炎症性自身免疫性疾病,主要影响成人,但有时孩子也会患该病。 该病的特征性损害为红色丘疹或斑块上覆有多层银白色鳞屑,好发于四肢伸侧、头皮和背部,严重皮损可泛发全身,并可出现高热、脓疱、红皮病样改变以及全身大小关节病变。主要病因为机体自身免疫系统变得活跃,并攻击机体自身正常组织。 银屑病患者具有患银屑病关节炎的风险,发生率为10-20%。出现银屑病关节炎的病因与出现银屑病为同一根本

Nat Commun:科学家揭示银屑病发病机理

银屑病(又称牛皮癣),是发病率高达的2%的炎性皮肤病,然而其发病的具体机制并不十分清楚。最近一些研究表明肠道微生物与自身免疫病的发生之间具有莫大的联系,而具体到银屑病与肠道微生物之间的关系也并不清楚。针对这一问题,来自美国NIH的WanJun Chen课题组做了相关研究,结果发表在最近一期的nature communication 杂志上。之前的研究发现:对小鼠的皮肤与耳部施加imiquimod

银屑病可增加患者抑郁症的发病风险

银屑病可增加患者抑郁症的发病风险银屑病是一种慢性自身免疫性疾病,主要侵犯皮肤。据2015年美国皮肤病学会夏季会议的一项新的研究显示,银屑病患者发生抑郁的风险更大。研究人员分析了全国健康与营养调查的数据,包括了12382名成人,部分为银屑病患者。结果显示,约16.5%的银屑病患者符合抑郁症的标准。校正了抑郁症发病危险因素(包括年龄,种族,性别,身体指数,体力活动,烟酒以及其他的疾病情况)后通过计算,

Baidu
map
Baidu
map
Baidu
map